Molecular Assemblies
Molecular Assemblies was a San Diego-based life-sciences tools company that developed proprietary Fully Enzymatic Synthesis (FES)™ enzymatic DNA synthesis technology to produce long, high-purity oligonucleotides up to 400 bases for enterprise customers in therapeutics, synthetic biology, agriculture, and data storage, and was acquired by Maravai LifeSciences/TriLink BioTechnologies in January 2025.
- Company typePrivate
- Founded2013
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Molecular Assemblies does
Molecular Assemblies was a privately held San Diego-based life-sciences tools company founded in 2013 that developed Fully Enzymatic Synthesis (FES)™, a proprietary enzymatic DNA synthesis technology designed as an alternative to traditional phosphoramidite chemistry. The core technical claim was a 99.9% step-wise incorporation efficiency versus the ~99.6% plateau of chemical synthesis, achieved through a terminal deoxynucleotidyl transferase-based process that operates at up to 70 °C and neutral pH. These conditions allow the platform to synthesize long, high-purity single-stranded oligonucleotides up to 400 bases, including traditionally difficult sequences with high or low GC content, long homopolymer stretches, and repetitive elements, without the need for post-synthesis PAGE or HPLC purification. The modular manufacturing platform was positioned to deliver faster order-to-shipment turnaround with predictable first-time pass rates.
The company targeted an enterprise B2B customer base across four primary use-case segments: therapeutics and vaccines, synthetic biology and genomics, agriculture and food, and DNA-based data storage. It sold DNA synthesis services and oligonucleotide products via direct field sales and its website (with a "Get Long Oligos Now" call-to-action), operating on a quote-based, non-publicly-disclosed pricing model. It carried no named enterprise customers and no disclosed revenue, indicating that commercial activity was nascent through its independent life. Molecular Assemblies was venture-backed, raising cumulative equity, grant, and corporate funding exceeding $60 million across rounds from 2013 through 2024, with a $25.8 million Series B in March 2022 representing the largest disclosed equity round. Strategic investors and partners included Agilent Technologies, Codexis, Casdin Capital, Alexandria Venture Investments, Argonautic Ventures, iSelect Fund, LYFE Capital, Keshif Ventures, and DCVC, alongside non-dilutive capital from the NIH (SBIR), NSF, and DARPA/GE Healthcare.
In January 2025, Molecular Assemblies' property and intellectual property were acquired by Maravai LifeSciences and integrated into TriLink BioTechnologies, ending independent operations. The technology continues to be offered under the Molecular Assemblies brand within TriLink's commercial portfolio.
Molecular Assemblies firmographics
Firmographics- Name
- Molecular Assemblies
- Legal name
- Molecular Assemblies, Inc.
- Website
- https://molecularassemblies.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Molecular Assemblies was a San Diego-based life-sciences tools company that developed proprietary Fully Enzymatic Synthesis (FES)™ enzymatic DNA synthesis technology to produce long, high-purity oligonucleotides up to 400 bases for enterprise customers in therapeutics, synthetic biology, agriculture, and data storage, and was acquired by Maravai LifeSciences/TriLink BioTechnologies in January 2025.
- Ownership category
- akta.pro rank
Molecular Assemblies industry classification
Industry- Product category
- DNA Synthesis Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where Molecular Assemblies is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Molecular Assemblies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- DNA Synthesis Services/Products: Molecular Assemblies produces and sells long, pure, and accurate DNA oligonucleotides synthesized using their proprietary Fully Enzymatic Synthesis technology. The modular manufacturing platform enables fast order-to-shipment turnaround times.
Go-to-market motion1 record
Distribution channels1 record
Molecular Assemblies product offering
Product offeringCore offering
Molecular Assemblies developed and sold long, pure, and accurate single-stranded DNA oligonucleotides produced through its proprietary Fully Enzymatic Synthesis (FES)™ enzymatic technology. The platform synthesizes DNA up to 400 bases in length at 99.9% step-wise incorporation efficiency, operating at temperatures up to 70°C and neutral pH without requiring post-synthesis PAGE or HPLC purification. The offering targeted enterprise customers in therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology applications requiring high-quality, long DNA sequences.
Product overview
Molecular Assemblies offered Fully Enzymatic Synthesis (FES)™ technology, a proprietary enzymatic DNA synthesis platform that produces long, pure, and accurate single-stranded DNA oligonucleotides up to 400 bases. The core technology operates at 99.9% step-wise incorporation efficiency (versus 99.6% for traditional chemical synthesis), using a neutral pH enzymatic process at up to 70°C that eliminates the need for post-synthesis PAGE or HPLC purification. The company targeted multiple application segments including therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology. Following Maravai LifeSciences' acquisition in January 2025, the assets and IP were integrated into TriLink BioTechnologies, with the technology now offered as part of TriLink's product portfolio under the Molecular Assemblies brand.
Differentiator
Problem solved
Functional benefit
Products and services
- Fully Enzymatic Synthesis (FES)™ DNA Synthesis Platform Proprietary enzymatic DNA synthesis platform that achieves 99.9% step-wise incorporation efficiency versus 99.6% for traditional chemical synthesis, enabling production of long, pure, and accurate DNA oligos up to 400 bases without the need for post-synthesis PAGE or HPLC purification. Sold to enterprise customers in therapeutics, vaccines, immunotherapy, agriculture, and synthetic biology.
- Long Single-Stranded Oligonucleotides DNA oligonucleotides produced using FES technology reaching up to 400 bases in length with high accuracy and purity through in-process purification; operates at up to 70°C to handle difficult secondary structures including high/low GC content, long homopolymer stretches, and repetitive elements. Offered as a custom synthesis product to enterprise customers.
Quantifiable outcome
- 99.9% step-wise incorporation efficiency (vs 99.6% for chemical synthesis)
- +2 more outcomes
Companies that use Molecular Assemblies
Customer profileSegments4 records
Ideal customer profiles3 records
Molecular Assemblies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Molecular Assemblies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Maravai LifeSciencesmajor
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Molecular Assemblies competitors and assessment
Company assessmentDirect peers
- DNA Script: DNA Script is the most direct competitor — also developing enzymatic DNA synthesis technology (Syntax platform) targeting long, high-fidelity oligonucleotides for similar applications in synthetic biology, therapeutics, and genomics. Both companies share the same core technical premise of replacing phosphoramidite chemistry with terminal deoxynucleotidyl transferase-based enzymatic synthesis.
- Twist Bioscience: Twist Bioscience is a leading DNA synthesis provider using silicon-based high-throughput chemical synthesis, directly competing with Molecular Assemblies in gene fragments, oligo pools, and synthetic biology tools. Twist serves overlapping customer segments (therapeutics, ag-bio, data storage) and represents the dominant incumbent that FES technology seeks to disrupt.
- Synbio Technologies: Synbio Technologies is a gene synthesis and oligo provider serving synthetic biology and therapeutics customers with chemical and emerging enzymatic methods. It competes in gene fragment and long oligo delivery directly with Molecular Assemblies' offering.
Emerging players
- Ansa Bio: Ansa Bio is an emerging player in enzymatic DNA synthesis, developing a polymerase-based platform for long, accurate oligonucleotides. It targets the same customer base as Molecular Assemblies in synthetic biology and therapeutics and represents a parallel technology approach to enzymatic synthesis.
- Catalog Technologies: Catalog Technologies is a DNA data storage company that depends on long, high-fidelity oligonucleotide synthesis — directly aligned with one of Molecular Assemblies' targeted applications. It serves as both a potential customer and adjacent player in the DNA-based data storage value chain.
Broad incumbents
- Integrated DNA Technologies (IDT): IDT is a long-established incumbent in custom oligonucleotide synthesis, acquired by Danaher. It serves the same therapeutic and research customers with a broad portfolio of chemically synthesized oligos, representing both a major competitor and a potential strategic acquirer in the same space.
- GenScript: GenScript is a major life sciences services provider with significant gene synthesis and oligo manufacturing capabilities. It serves overlapping synthetic biology and therapeutic customers globally and competes across the DNA synthesis value chain.
- Eurofins Genomics: Eurofins Genomics operates one of the largest commercial DNA oligonucleotide synthesis operations globally, serving research, diagnostic, and therapeutic customers. It is a broad incumbent with significant scale in chemically synthesized oligos.
Others
- Codexis: Codexis is a protein engineering company and Molecular Assemblies' investor (via SynBio Innovation Accelerator). It is an enabling/partner company providing enzyme engineering capabilities relevant to enzymatic DNA synthesis and represents an adjacent technology platform.
- TriLink BioTechnologies: TriLink BioTechnologies acquired Molecular Assemblies' IP and assets in January 2025 and now commercializes the FES technology under the Molecular Assemblies brand. It is an enabling platform/integrator that serves the same customer base as a nucleic acid manufacturing partner.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks7 records
Key highlights5 records
Customer concentration
Molecular Assemblies social profiles
Digital presenceMolecular Assemblies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular Assemblies leadership team
Management profileNumber of profiles
Profiles6 records
Molecular Assemblies funding detail
Funding detailFunding overview
Funding rounds10 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular Assemblies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular Assemblies
What does Molecular Assemblies do?
Molecular Assemblies developed and sold long, pure, and accurate single-stranded DNA oligonucleotides produced through its proprietary Fully Enzymatic Synthesis (FES)™ enzymatic technology. The platform synthesizes DNA up to 400 bases in length at 99.9% step-wise incorporation efficiency, operating at temperatures up to 70°C and neutral pH without requiring post-synthesis PAGE or HPLC purification. The offering targeted enterprise customers in therapeutics/vaccines, immunotherapy, agriculture, and nanotechnology applications requiring high-quality, long DNA sequences.
Is Molecular Assemblies a public or private company?
Molecular Assemblies is a private company. It is classified as venture growth investor backed and is currently acquired.
When was Molecular Assemblies founded?
Molecular Assemblies was founded in 2013. It employs 1 to 10 people.
Where is Molecular Assemblies based?
Molecular Assemblies is headquartered in San Diego, United States, in the North America region.
How does Molecular Assemblies make money?
One revenue line is on record: DNA Synthesis Services/Products.
Who are Molecular Assemblies's main competitors?
Direct peers on record are DNA Script, Twist Bioscience and Synbio Technologies. Emerging players are Ansa Bio and Catalog Technologies. Broad incumbents are Integrated DNA Technologies (IDT), GenScript and Eurofins Genomics. Others are Codexis and TriLink BioTechnologies.
Does Molecular Assemblies have an API?
No public API is recorded for Molecular Assemblies.
What industry is Molecular Assemblies in?
Molecular Assemblies's product category is DNA Synthesis Services. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2834.